Trial Profile
A Randomized, Open-label, Controlled Study To Evaluate The Efficacy And Safety Of Dual Anti-inflammatory Combination Of Fluticasone And Roflumilast In Patients With Chronic Obstructive Pulmonary Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary) ; Salmeterol/fluticasone propionate (Primary) ; Tiotropium bromide (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- 18 Aug 2015 New trial record